---
title: "查爾丹資本維持對紫色生物科技的買入評級，維持 11 美元的目標股價。"
description: "Chardan Capital 的分析師 Daniil Gataulin 維持對 Purple Biotech（納斯達克股票代碼：PPBT）的買入評級，並維持 11 美元的目標股價。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/109478642.md"
published_at: "2024-03-07T19:01:20.000Z"
---

# 查爾丹資本維持對紫色生物科技的買入評級，維持 11 美元的目標股價。

> Chardan Capital 的分析師 Daniil Gataulin 維持對 Purple Biotech（納斯達克股票代碼：PPBT）的買入評級，並維持 11 美元的目標股價。

Chardan Capital 的分析師 Daniil Gataulin 維持對 Purple Biotech（納斯達克股票代碼：PPBT）的買入評級，並維持 11 美元的目標股價。

### Related Stocks

- [PPBT.US - Purple Biotech](https://longbridge.com/zh-HK/quote/PPBT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| XBI vs. IBB: Which Biotech ETF do Analysts Prefer in 2026? | In 2026, Biotech ETFs, particularly the SPDR S&P Biotech ETF (XBI) and iShares Biotechnology ETF (IBB), are gaining atte | [Link](https://longbridge.com/zh-HK/news/276158809.md) |
| Will Early ERAS-0015 Signals at Guggenheim Summit Reshape Erasca's (ERAS) RAS Pipeline Narrative? | Erasca presented at the Guggenheim Securities’ Biotech Summit, discussing its ERAS-0015 and ERAS-4001 programs, highligh | [Link](https://longbridge.com/zh-HK/news/276107056.md) |
| A Look At Savara (SVRA) Valuation After Recent FDA Progress And Strengthened Outlook | Savara (SVRA) is gaining investor attention following its recent FDA progress, including a resubmitted biologics license | [Link](https://longbridge.com/zh-HK/news/276201245.md) |
| ALK-Abello Tops Q4 Estimates and Revives Dividend with Confident 2026 Outlook | Danish biotech ALK-Abello A/S reported a strong Q4 performance with sales of DKK1.73 billion, exceeding forecasts by 3%. | [Link](https://longbridge.com/zh-HK/news/276440262.md) |
| BB Biotech Benefits from Improved Market Environment | BB Biotech has reported a net profit of 578 million francs for 2025, significantly up from 76 million francs in 2024. Th | [Link](https://longbridge.com/zh-HK/news/276427224.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。
